Everything below concerns AOD-9604. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Last reviewed on 2025-10-22. Where a claim depends on a specific study, the study is described rather than over-claimed.
AOD-9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It corresponds to residues 176-191 of the 191-amino-acid hGH sequence. The fragment is not the full hormone and lacks the receptor-binding region associated with growth and metabolic effects of hGH. Researchers developed it to isolate a specific portion of hGH for study. Its exact sequence and length are often stated in peptide catalogs and patents.
The peptide is frequently described as a growth hormone fragment, although it is chemically distinct from full-length hGH. AOD-9604 contains 16 amino acids and includes two cysteine residues that can form an intramolecular disulfide bond. In solution, this structural feature can influence folding, aggregation, and stability. Published descriptions sometimes call it hGH 176-191 or AOD9604, with spacing and capitalization varying. Such naming differences can complicate literature searches, database entries, and product verification.
Regulatory treatment of AOD-9604 has varied. In sports anti-doping, the peptide became widely discussed during a 2013 investigation into an Australian professional sports club. Authorities at the time debated whether it fell under prohibitions on growth hormone and related substances. Later clarifications and updated lists have addressed the compound in different ways. Anyone seeking current status should consult the latest applicable rules, and commercial supply for human use is not authorized in major markets.
Research interest in AOD-9604 often focuses on whether it can influence lipid metabolism without the growth-promoting or glucose-related effects of full-length hGH. This question remains unresolved, and findings depend on model, dose, and measurement method. Some reviews treat the peptide as a historical obesity candidate rather than an active therapeutic. Others cite it in discussions of peptide fragments, metabolic signaling, and performance-enhancing substances. Clear conclusions are limited by the small number of rigorous, independent human studies.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic peptide | Derived from a fragment of human growth hormone |
| Sequence basis | hGH residues 176-191 | Commonly described as a 16-amino-acid fragment |
| Appearance | White to off-white powder | Typical for lyophilized research peptides |
| Solubility | Soluble in water or aqueous buffer | Exact solubility depends on pH and purity |
| Common synonyms | AOD9604; hGH 176-191 | Spelling and punctuation vary across sources |
AOD-9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It is often described as hGH fragment 176-191. Research interest arose because it was designed to isolate possible effects on fat metabolism from other actions of growth hormone. It is not a full growth hormone molecule. Its development history includes early laboratory and animal studies followed by human trials. The peptide has been examined in laboratory, animal, and limited human studies.
The compound has been studied as a potential treatment for obesity and related metabolic conditions. Published trials have examined changes in body weight, fat mass, and safety markers over limited durations. Results have been mixed or modest, and no large-scale outcome trials are established. Regulatory agencies in several countries have not approved it as a therapeutic drug. Some commercial products have been marketed outside regulated pharmaceutical channels, which raises questions about quality and claims.
In the scientific literature, AOD-9604 appears in reviews of growth hormone fragments and in discussions of peptide-based metabolic research. Some sources distinguish it from growth hormone itself, while others group it with compounds marketed for weight management. The evidence base is small compared with approved obesity medications. Questions about long-term efficacy and clinical relevance remain open, and independent replication of key findings is limited. Most published reports are early-stage and exploratory.
Research has examined whether the peptide affects fat mass independently of growth hormone's other actions. Early animal studies suggested reductions in body fat, but species differences and small sample sizes limit interpretation. Human studies have generally been short and have not consistently shown large effects. Some trials measured body composition, lipid profiles, and safety parameters, but the overall picture is one of suggestive yet inconclusive metabolic activity. Findings vary across study populations and protocols.
A central uncertainty is whether observed metabolic changes translate into meaningful clinical benefits. Study designs vary in dose, duration, and participant characteristics, making comparisons difficult. Independent replication is limited, and the field lacks consensus on optimal endpoints or treatment duration. Ongoing or future studies may clarify mechanism and effect size, but current evidence does not establish a clear therapeutic role. Researchers often call for larger, longer, and better-controlled trials, while questions remain about which patient groups might respond.
Proposed mechanism focuses on lipolysis, the breakdown of stored triglycerides into free fatty acids and glycerol. AOD-9604 is thought to act on adipose tissue without stimulating appetite or affecting blood sugar in the same way as growth hormone. Laboratory studies report increased fat oxidation in some models. The precise receptor interactions and signaling pathways remain incompletely characterized. Researchers have proposed that the peptide may influence fat mobilization through pathways distinct from the full hormone.
== Adverse effects == Cipaglucosidase alfa in combination with miglustat may cause serious side effects including life-threatening allergic reactions during and after the infusion and harm to an unborn baby if taken while pregnant. The most common side effects of cipaglucosidase alfa in combination with miglustat are headache, diarrhea, fatigue, nausea, abdominal pain, and fever.
The goal of gender-affirming surgery is to align the secondary sexual characteristics of transgender people with their gender identity. As hormone replacement therapy, gender-affirming surgery is also employed as a response to diagnosis gender dysphoria The World Professional Association for Transgender Health (WPATH) Standards of Care recommend additional requirements for gender-affirming surgery when compared to hormone replacement therapy. Whereas hormone replacement therapy can be obtained through something as simple as an informed consent form, gender-affirming surgery can require a supporting letter from a licensed therapist (two letters for genital surgery such as vaginoplasty or phalloplasty), hormonal treatment, and (for genital surgery) completion of a 12-month period in which the person lives full-time as their gender. WPATH standards, while commonly used in gender clinics, are non-binding; many trans patients undergoing surgery do not meet all of the eligibility criteria.
The Morgan State University Choir has performed for audiences throughout the United States and internationally. Robert Shaw has directed them, together with the Orchestra of St. Lukes and Jessye Norman and others in Carnegie Hall's One Hundredth Birthday Tribute to Marian Anderson. In the 1996-1997 season, the "Silver Anniversary" concert was broadcast throughout the state of Maryland. The concert won an Emmy Award for Maryland Public Television. During 2011-2012 academic years, the choir had several prominent performances. Since 2017, the Morgan State University choir has toured Cuba, Spain, Portugal, Austria, Slovakia, Germany, England, Scotland, Wales, Peru, Ecuador, and the Galapagos Islands. In December 2021, the choir sang a concert in Hawaii, to commemorate the eightieth anniversary of the bombing of Pearl Harbor.
=== Lactation === Its use in breastfeeding mothers not recommended as it is excreted in breast milk and the concentration found in breast milk is approximately a quarter that of the maternal serum level.
Sources: en.wikipedia.org
It also announces that it will no longer grant blanket immunity to politicians who use its service, especially if their posts are deemed to be deceptive or abusive. District Judge Roger Benitez overturns California's ban on assault weapons. A letter to Apple's Tim Cook is made public, in which staff request more flexibility over remote work, following the company's decision to return its 150,000 employees to the office. The FDA approves the first new medication since 2014, semaglutide (Wegovy), for chronic weight management. June 5 – Aftermath of the January 6 United States Capitol attack – The Department of Justice says that over 465 people have been arrested since the January 6 attack. It is also seeking information on 250 other suspects. June 6 Aftermath of the January 6 United States Capitol attack – Rep. Eric Swalwell (D–CA) announces he sued Mo Brooks (R–AL) for being responsible for inciting January 6. COVID-19 vaccination in the United States: The U.S. surpasses 300 million COVID-19 vaccine doses administered. Floyd Mayweather fights in an exhibition bout against YouTuber Logan Paul. The United States defeats Mexico 3–2 after extra time in the final to become the first champions of the CONCACAF Nations League. June 7 Twitter suspensions: Twitter announces that they have suspended the account of former Florida Department of Health dashboard manager Rebekah Jones for spamming and "platform manipulation" after she paid other users to follow her. Aducanumab (Aduhelm), the first new medication for Alzheimer's disease in 20 years, is approved by the FDA.
ATP synthase, also called complex V, is the final enzyme in the oxidative phosphorylation pathway. This enzyme is found in all forms of life and functions in the same way in both prokaryotes and eukaryotes. The enzyme uses the energy stored in a proton gradient across a membrane to drive the synthesis of ATP from ADP and phosphate (Pi). Estimates of the number of protons required to synthesize one ATP have ranged from three to four, with some suggesting cells can vary this ratio, to suit different conditions.
In Peru, on 29 January 1821, Viceroy Pezuela was deposed in a coup d'état by José de la Serna, but it would be two months before San Martín moved his army closer to Lima by sailing it to Ancón. During the next few months San Martín once again engaged in negotiations, offering the creation of an independent monarchy; but La Serna insisted on the unity of the Spanish monarchy, so the negotiations came to nothing. By July La Serna judged his hold on Lima to be weak, and on 8 July the royal army abandoned the coastal city to reinforce positions in the highlands, with Cuzco as new capital of the viceroyalty. On the 12th San Martín entered Lima, where he was declared "Protector of the Country" on 28 July, an office which allowed him to rule the newly independent state.
Sources: en.wikipedia.org
No, it is a synthetic peptide fragment corresponding to a small portion of hGH. It is not the full 191-amino-acid hormone and does not reproduce all of hGH's effects.
It is commonly described as a 16-amino-acid peptide based on residues 176-191 of human growth hormone. Some sources vary in notation, so checking the stated sequence is useful.
It is not typically described as a standalone natural hormone. The sequence is derived from the C-terminal region of human growth hormone, but the synthetic peptide is a laboratory-made construct.
No major medicines regulator appears to have approved AOD-9604 for human therapeutic use. It has been studied in clinical trials, but those programs did not result in a marketed drug.